Hemispherx BioPharma, Inc (NYSE:HEB) was the target of a significant decrease in short interest during the month of October. As of October 13th, there was short interest totalling 1,044,475 shares, a decrease of 5.1% from the September 29th total of 1,100,251 shares. Based on an average daily volume of 409,699 shares, the days-to-cover ratio is presently 2.5 days. Currently, 3.8% of the shares of the stock are short sold.
An institutional investor recently raised its position in Hemispherx BioPharma stock. Vanguard Group Inc. raised its holdings in Hemispherx BioPharma, Inc (NYSE:HEB) by 0.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 453,805 shares of the specialty pharmaceutical company’s stock after buying an additional 2,709 shares during the period. Vanguard Group Inc. owned about 1.56% of Hemispherx BioPharma worth $227,000 as of its most recent filing with the Securities and Exchange Commission.
Hemispherx BioPharma (NYSE HEB) opened at 0.316 on Friday. The firm has a 50-day moving average of $0.33 and a 200-day moving average of $0.46. The company’s market capitalization is $9.22 million. Hemispherx BioPharma has a 52 week low of $0.30 and a 52 week high of $1.08.
Hemispherx BioPharma (NYSE:HEB) last posted its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter. Hemispherx BioPharma had a negative net margin of 1,029.58% and a negative return on equity of 75.57%. The firm had revenue of $0.21 million during the quarter. Equities analysts expect that Hemispherx BioPharma will post $0.00 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/28/hemispherx-biopharma-inc-heb-sees-large-decline-in-short-interest.html.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.